<?xml version="1.0" encoding="UTF-8"?>
<ref id="bib0049">
 <label>49</label>
 <element-citation publication-type="journal" id="sbref0049">
  <person-group person-group-type="author">
   <name>
    <surname>Li</surname>
    <given-names>JX</given-names>
   </name>
   <name>
    <surname>Hou</surname>
    <given-names>LH</given-names>
   </name>
   <name>
    <surname>Meng</surname>
    <given-names>FY</given-names>
   </name>
   <name>
    <surname>Wu</surname>
    <given-names>SP</given-names>
   </name>
   <name>
    <surname>Hu</surname>
    <given-names>YM</given-names>
   </name>
   <name>
    <surname>Liang</surname>
    <given-names>Q</given-names>
   </name>
  </person-group>
  <article-title>Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial</article-title>
  <source>Lancet Glob Health</source>
  <volume>5</volume>
  <year>2017</year>
  <fpage>e324</fpage>
  <lpage>e334</lpage>
  <pub-id pub-id-type="pmid">28017642</pub-id>
 </element-citation>
</ref>
